Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE)
Diseases of the Cardiovascular System | Diseases of the Nervous System
What is the purpose of this trial?
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
- Ages18 years and older
- Trial withUniversity of Cincinnati
- Start Date06/19/2020
- End Date04/30/2024
- Last Updated11/15/2021
- Study HIC#2000026409